Key facts, as of
As of November 6, 2026, Bio-Techne Corporation (TECH) trades at $72.78, up 25.1% over the past year. It is at the top of its 52-week range ($43.20 to $72.83). It is 46.5% below its all-time high of $135.96, reached in September 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +196.5%, against +316.3% for the S&P 500 (SPY). It sits 15.1% above its 200-day average of $63.23, and its 50-day average is above the 200-day too: an uptrend on both averages. Its 30-day volatility is 1.5% annualized, which we rate low risk. It has a trailing P/E of 62.7 and a dividend yield of 0.44%.
Cite: Portfolio Terminal, "Bio-Techne Corporation (TECH) stock analysis", 2026-11-06. https://portfolio-terminal.com/analyse/tech
Where it trades today
trading 100% of the way up its 52-week range
How the price has moved
How far it is from its record
Bio-Techne Corporation (TECH) is 46.5% below its all-time high of $135.96, reached in September 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +196.5%, against +316.3% for the S&P 500 (SPY).
The read, from its own figures
What its numbers say
- TECH closes above its 50-day average ($72.48), and the 50-day sits above the 200-day ($63.23): on both averages the chart reads as an uptrend.
- At $72.78, TECH is within 1% of its 1-year high of $72.83, set on November 4, 2026; it is 68.5% above its 1-year low of $43.20 (May 15, 2026).
- Over the past month TECH rose 0.5%, from $72.45 to $72.78.
- TECH trades at 62.7x its last twelve months of earnings and 31.5x the next twelve months' estimate, so analysts expect earnings 99.3% higher.
- Its P/E is 127.3% above the 27.6x median of the 2 other biotechnology companies we track (VRTX, REGN).
- TECH's 30-day volatility, 1.5% a year, works out to a typical daily move of about 0.1%.
- Yahoo Finance puts its beta at 1.27: over five years of monthly returns, TECH moved about 1.27% for each 1% move of the S&P 500.
What would change the read
- A close under the 50-day average, $72.48 (−0.4% from the last close), would turn the read to a pullback; under the 200-day, $63.23 (−13.1%), the longer rise is in question.
- A close above $72.83 (+0.1%) would be a new 1-year high; below $43.20 (−40.6%), a new 1-year low.
How it is computed
- Prices are Yahoo Finance's daily candles for TECH, the same ones the chart below draws; the P/E, forward P/E and beta are Yahoo Finance quote fields.
- The averages are simple means of the last 50 and 200 closes; the 1-year high and low are the highest high and lowest low of the last 252 sessions; the 30-day volatility is the standard deviation of the past month's daily returns, annualized with the square root of 252.
- Peers are the other companies Yahoo Finance files under biotechnology among the assets we track, not a full industry screen; the median counts those with a positive P/E.
- Every sentence here is written by code from those figures, refreshed daily; nobody edits it for TECH by hand. It describes what the price and the multiples have done, not what they will do, and it is not advice.
Sources
- Yahoo Finance quote and daily historyopen →
The candles, the averages' inputs and the quote fields used for TECH. Last refresh: Nov 8, 2026, 10:53 PM UTC.
- How Portfolio Terminal computes its figuresopen →
The methodology page behind the analytics and their refresh cadence.
- Industry classification
Yahoo Finance's industry, as stored in our list of tracked assets: Biotechnology.
What Bio-Techne Corporation does
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow…
What analysts expect
TECH carries a hold consensus from 10 analysts, with an average price target of $70.50 versus $72.78 today (-3.1%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
TECH generated $1.23B in trailing revenue (4.6% year over year), with a 14.0% net margin, and $277.76M of free cash flow, supported by $65.57M of net cash.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2026 | $1.22B | $799.07M | $272.61M | $181.86M | $1.17 | $263.22M |
| 2025 | $1.22B | $790.27M | $242.80M | $73.40M | $0.47 | $256.55M |
| 2024 | $1.16B | $769.73M | $246.40M | $168.10M | $1.07 | $236.10M |
| 2023 | $1.14B | $769.82M | $291.00M | $285.26M | $1.81 | $216.15M |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
TECH is in 11 of the 54 ETFs we track. It weighs most in RSP: 0.20% of the fund, holding #249 of 504.
Famous investors who hold it
TECH is in the latest 13F of 1 of the 15 famous investors we follow. George Soros (Soros Fund Management) holds the most of it: 0.46% of the portfolio, position #65 of 261, as of Q2 2026.
How its figures compare with those peers
Companies in the same industry
TECH beside the other companies Yahoo Finance files under biotechnology among the assets we track (VRTX, REGN, MRNA, largest first).
TECHyou are here$72.78$11.43B
VRTXVertex Pharmaceuticals$547.09$138.71B
REGNRegeneron Pharmaceuticals$904.35$93.55B
MRNAModerna Inc.$254.19$102.85BWhat the chart is saying
Trading at its high for the year, with no resistance overhead.
uptrend- Price is 0.4% above its 50-day average and 15.1% above its 200-day.
- The 50-day crossed above the 200-day on 2026-07-24 (a “golden cross”).
- RSI at 61 is neither stretched nor washed out.
- Nothing above has stopped it this year; the nearest floor is $70.55 (-3.1%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
How is TECH valued right now?
Bio-Techne Corporation trades at 62.7 times its last twelve months of earnings and 31.5 times the next twelve months' estimate (Yahoo Finance, November 6, 2026). On the chart: trading at its high for the year, with no resistance overhead. Price is 0.4% above its 50-day average and 15.1% above its 200-day.
What is the risk level of TECH?
Based on 30-day volatility of 1.5%, TECH has LOW risk. Its beta of 1.27 means it has swung more than the S&P 500 over the last five years.
Does TECH pay dividends?
Yes, Bio-Techne Corporation has a dividend yield of 0.44%.
How far is TECH from its all-time high?
Bio-Techne Corporation is 46.5% below its all-time high of $135.96, reached in September 2021. Over the 10 years to the end of October 2026, with dividends reinvested, it returned +196.5%, against +316.3% for the S&P 500 (SPY).
Which ETFs hold TECH?
11 of the 54 popular ETFs we track hold Bio-Techne Corporation. The largest weights: RSP (0.20%), XLV (0.18%), VB (0.14%), CSPX (0.02%) and SPY (0.02%). Measured on each issuer's full holdings file, dated September 30 to October 18, 2026.
How much of VOO is TECH?
0.02%, as of September 30, 2026: TECH is holding #463 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $0.17 in Bio-Techne Corporation.
Which famous investors own TECH?
George Soros (0.46% of Soros Fund Management's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for TECH?
The average analyst price target for Bio-Techne Corporation (TECH) is $70.50 based on 10 analyst estimates, about 3.1% below the current price of $72.78. The published range runs from $50.00 to $73.00.
How much revenue does TECH generate?
Bio-Techne Corporation reported $1.23B in trailing twelve-month revenue. Revenue growth is running at 4.6% year over year. Net margin sits at 14.0%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare TECH with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.